Philip N. Newsome

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu et al. · Hepatology · 2023 · 2.5K citations · Full text

Evidence-based Medicine, Pathology, Fatty Liver Disease +16

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

Matthew J. Armstrong, Piers Gaunt, Guruprasad P. Aithal et al. · The Lancet · 2015 · 2K citations · Full text

Placebo-controlled Phase 2, Liraglutide Safety, Hepatology +5

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

Philip N. Newsome, Kristine Buchholtz, Kenneth Cusi et al. · New England Journal of Medicine · 2020 · 1.7K citations · Full text

Resolving the fibrotic niche of human liver cirrhosis at single-cell level

Prakash Ramachandran, Ross Dobie, John R. Wilson‐Kanamori et al. · Nature · 2019 · 1.6K citations · Full text

Single-cell Level, Fibrosis, Hepatology +12

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Stephen A. Harrison, Pierre Bédossa, Cynthia D. Guy et al. · New England Journal of Medicine · 2024 · 1.4K citations · Full text